![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Voyager V-1 (VSV-IFNbeta-NIS) is based on the VSV platform. Voyager-V1 is designed for enhanced safety, efficacy, and traceability through the inclusion of the interferon beta gene, enabling the virus to: replicate quickly in cancer cells without damaging healthy cells.
Lead Product(s): VSV-IFNbeta-NIS,Ruxolitinib Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Voyager-V1
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
Study combines Vyriad’s oncolytic virus Voyager-V1 and the PD-1 inhibitor Libtayo® (cemiplimab) in skin, lung, liver and uterine cancer.
Lead Product(s): Voyager-V1,Cemiplimab
Therapeutic Area: Oncology Product Name: Voyager-V1
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020